Resources
Learn from our library of research publications and other educational materials.
The information on this website is provided for the education of healthcare professionals only and may contain information not approved by the US Food and Drug Administration.
Select a resource type.
Select a topic.
Select a resource type.
Select a topic.
Calcifediol as a therapeutic
Adams JS, Shieh A, Bishop CW
Chapter 73 of Feldman and Pike’s Vitamin D, Fifth Edition, Volume Two: Health, Disease and Therapeutics
2024
Single-dose pharmacokinetics of extended-release calcifediol (ERC) in healthy Japanese and non-Japanese volunteers
Bishop CW, Ashfaq A
Presented at the European Renal Association Congress
2025
Managing dysregulated vitamin D metabolism in CKD: time to update conventional wisdom?
Bishop CW, Ashfaq A, Choe J, Norris KC, Sprague SM
Kidney360
2025
Vitamin D metabolome (VDM) profiles after single and repeated doses of extended-release calcifediol (ERC) in hemodialysis (HD) patients
Bishop CW, Choe J, Ashfaq A
Presented at the American Society of Nephrology Annual Meeting
2025
Effect of race, gender and age on intrinsic diurnal variation of serum calcifediol: insights into vitamin D toxicity
Bishop CW, Choe J, Strugnell SA, Tabash S, Ashfaq A
J Steroid Biochem Mol Biol
2026
Control of secondary hyperparathyroidism with extended-release calcifediol is associated with slower CKD progression
Bishop CW, Strugnell SA, Ashfaq A
Presented at the American Society of Nephrology Annual Meeting
2023
Extended-release calcifediol overcomes impact of low eGFR on vitamin D metabolism
Bishop CW, Strugnell SA, Ashfaq A, et al
Presented at the American Society of Nephrology Annual Meeting
2023
Vitamin D and secondary hyperparathyroidism in chronic kidney disease: a critical appraisal of the past, present, and the future
Brandenburg V, Ketteler M
Nutrients
2022
Does correction of secondary hyperparathyroidism with extended-release calcifediol provide renoprotection?
de Borst MH
Am J Nephrol
2024
Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency
Galassi A, Ciceri P, Porata G, et al
Expert Opin Drug Saf
2021
Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients
Germain MJ, Paul SK, Fadda G, et al
BMC Nephrol
2022
The role of nutritional vitamin D in chronic kidney disease-mineral and bone disorder in children and adults with chronic kidney disease, on dialysis, and after kidney transplantation–a European consensus statement
Jørgensen HS, Vervloet M, Cavalier E, et al
Nephrol Dial Transplant
2025
Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease
Ketteler M, Ambühl P
J Nephrol
2021
Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s
Ketteler M, Bover J, Mazzaferro S
Nephrol Dial Transplant
2023
A systematic review of the pharmacotherapy of secondary hyperparathyroidism (SHPT) in grades 3-5 chronic kidney disease (CKD)
Miedziaszczyk M, Idasiak-Piechocka I, Wiśniewski OW, Lacka K
Eur Rev Med Pharmacol Sci
2022
Have questions or need more information?
Contact Medical Affairs